메뉴 건너뛰기




Volumn 6, Issue 4, 2009, Pages 389-404

New drug delivery strategies for improved Parkinson's disease therapy

Author keywords

Anti Parkinson; Codrugs; Dendrimers; Nanoparticles; Transdermal delivery

Indexed keywords

'AIR'; AMANTADINE; AMR 103; APO GO AMPOULES; APO GO PEN; APO GO PFS; APOMORPHINE; ARTANE RETARD; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BENZATROPINE MESILATE; BIPERIDEN; BORNAPRINE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DAVERIUM; DIHYDROERGOCRYPTINE; ENTACAPONE; ETILEVODOPA; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; LISURIDE MALEATE; METIXENE; NENAD; NENAD SC; NENAD TDS; OLANZAPINE; ORPHENADRINE; PERGOLIDE; PERGOLIDE MESILATE; PLACEBO; PRAMIPEXOLE; PROCYCLIDINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; V 1512; VR 040;

EID: 67649116292     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902870405     Document Type: Review
Times cited : (57)

References (193)
  • 1
    • 33644543761 scopus 로고    scopus 로고
    • Expanding insights of mitochondrial dysfunction in Parkinson's disease
    • DOI 10.1038/nrn1868, PII N1868
    • Abou-Sleiman PM, Muqit MMK, Wood NW, et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207-219 (Pubitemid 43292466)
    • (2006) Nature Reviews Neuroscience , vol.7 , Issue.3 , pp. 207-219
    • Abou-Sleiman, P.M.1    Muqit, M.M.K.2    Wood, N.W.3
  • 2
    • 33847105184 scopus 로고    scopus 로고
    • Advances in the treatment of Parkinson's disease
    • DOI 10.1016/j.pneurobio.2006.11.009, PII S0301008206001511
    • Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease. Prog Neurobiol 2007;81:29-44 (Pubitemid 46282270)
    • (2007) Progress in Neurobiology , vol.81 , Issue.1 , pp. 29-44
    • Singh, N.1    Pillay, V.2    Choonara, Y.E.3
  • 3
    • 57349093766 scopus 로고    scopus 로고
    • Levodopa for the treatment of Parkinson's Disease
    • • This review provides a discussion of mechanism, benefits and problems related to LD therapy from a clinical point of view
    • LeWitt PA. Levodopa for the treatment of Parkinson's Disease. N Engl J Med 2008;359:2468-2476 • This review provides a discussion of mechanism, benefits and problems related to LD therapy from a clinical point of view.
    • (2008) N Engl J Med , vol.359 , pp. 2468-2476
    • LeWitt, P.A.1
  • 4
    • 0033934604 scopus 로고    scopus 로고
    • Entacapone and selegiline with L-dopa in patients with Parkinson's disease: An interaction study
    • DOI 10.1016/S1353-8020(00)00012-2, PII S1353802000000122
    • Lyytinen J, Kaakkola S, Gordin A, et al. Entacapone and selegiline with L-dopa patients with Parkinson's disease: an interaction study. Parkinsonism Relat Disord 2000;6:215-222 (Pubitemid 30438779)
    • (2000) Parkinsonism and Related Disorders , vol.6 , Issue.4 , pp. 215-222
    • Lyytinen, J.1    Kaakkola, S.2    Gordin, A.3    Kultalahti, E.-R.4    Teravainen, H.5
  • 5
    • 0036798244 scopus 로고    scopus 로고
    • Dopaminergic substitution in Parkinson's disease
    • DOI 10.1517/14656566.3.10.1393
    • Müller T. Dopaminergic substitution in Parkinson's Disease. Expert Opin Pharmacother 2002;2:1393-1403 (Pubitemid 35174871)
    • (2002) Expert Opinion on Pharmacotherapy , vol.3 , Issue.10 , pp. 1393-1403
    • Muller, T.1
  • 6
    • 0031106236 scopus 로고    scopus 로고
    • New strategies with dopaminergic drugs: Modified formulations of levodopa and novel agonists
    • DOI 10.1006/exnr.1996.6381
    • Goetz CG. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Exp Neurol 1997;144:17-20 (Pubitemid 27149596)
    • (1997) Experimental Neurology , vol.144 , Issue.1 , pp. 17-20
    • Goetz, C.G.1
  • 8
    • 26444597591 scopus 로고    scopus 로고
    • Does levodopa slow or hasten the rate of progression of Parkinson's Disease?
    • Parkinson Study Group
    • Fahn S. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's Disease? J Neurol 2005;252:37-42
    • (2005) J Neurol , vol.252 , pp. 37-42
    • Fahn, S.1
  • 9
    • 7944236868 scopus 로고    scopus 로고
    • Clinical advantages of COMT inhibition with entacapone - A review
    • DOI 10.1007/s00702-004-0190-3, Parkinson's Research in Progress
    • Gordin A, Kaakkola S, Teräväinen H. Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 2004;111:1343-1363 (Pubitemid 39468395)
    • (2004) Journal of Neural Transmission , vol.111 , Issue.10-11 , pp. 1343-1363
    • Gordin, A.1    Kaakkola, S.2    Teravainen, H.3
  • 10
    • 67349157116 scopus 로고    scopus 로고
    • Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
    • published on line 20 February 2009, doi:10.1007/s00228-009-0622-y
    • Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009: published on line 20 February 2009, doi:10.1007/s00228-009-0622-y
    • (2009) Eur J Clin Pharmacol
    • Kuoppamäki, M.1    Korpela, K.2    Marttila, R.3
  • 12
    • 3843063551 scopus 로고    scopus 로고
    • Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: Results of a large multicentre open-label study
    • Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004;111:1053-1063 (Pubitemid 39037126)
    • (2004) Journal of Neural Transmission , vol.111 , Issue.8 , pp. 1053-1063
    • Onofrj, M.1    Thomas, A.2    Vingerhoets, F.3    Martin, W.4    Gimenez-Roldan, S.5    Azulay, J.-P.6    Bernhard, G.7    Schmidt, W.8    Markabi, S.9
  • 13
    • 0031773064 scopus 로고    scopus 로고
    • Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
    • Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314 (Pubitemid 28520549)
    • (1998) Neurology , vol.51 , Issue.5 , pp. 1309-1314
    • Rinne, U.K.1    Larsen, J.P.2    Siden, A.3    Worm-Petersen, J.4
  • 14
    • 0031028464 scopus 로고    scopus 로고
    • Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
    • Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87 (Pubitemid 27039521)
    • (1997) Neurology , vol.48 , Issue.1 , pp. 81-87
    • Kurth, M.C.1    Adler, C.H.2    St Hilaire, M.3    Singer, C.4    Waters, C.5    Lewitt, P.6    Chernik, D.A.7    Dorflinger, E.E.8    Yoo, K.9
  • 15
    • 0030880324 scopus 로고    scopus 로고
    • Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients
    • Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428
    • (1997) J Neurol Neurosurg Psychiatry , vol.63 , pp. 421-428
    • Baas, H.1    Beiske, A.G.2    Ghika, J.3
  • 16
    • 0030778373 scopus 로고    scopus 로고
    • Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
    • DOI 10.1002/ana.410420511
    • Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42:747-755 (Pubitemid 27481547)
    • (1997) Annals of Neurology , vol.42 , Issue.5 , pp. 747-755
    • Kieburtz1
  • 18
    • 34848821970 scopus 로고    scopus 로고
    • Tolcapone: An efficacy and safety review
    • Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review. Clin Neuropharmacol 2007;30:287-294
    • (2007) Clin Neuropharmacol , vol.30 , pp. 287-294
    • Olanow, C.W.1    Watkins, P.B.2
  • 19
    • 20544431978 scopus 로고    scopus 로고
    • Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy
    • DOI 10.1002/mds.20457
    • Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005;20:3-10 (Pubitemid 40846905)
    • (2005) Movement Disorders , vol.20 , Issue.SUPPL. 11
    • Olanow, C.W.1    Jankovic, J.2
  • 20
    • 41549097751 scopus 로고    scopus 로고
    • Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: Implications from a clinical and patient perspective
    • Brooks DJ. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 2008;4:39-47
    • (2008) Neuropsychiatr Dis Treat , vol.4 , pp. 39-47
    • Brooks, D.J.1
  • 21
    • 0023722336 scopus 로고
    • Controlled-release Sinemet (CR-4): A double-blind crossover study in patients with fluctuating Parkinson's disease
    • Ahlskog JE, Muenter MD, Mcmanis PG. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 1988;63:867-886
    • (1988) Mayo Clin Proc , vol.63 , pp. 867-886
    • Ahlskog, J.E.1    Muenter, M.D.2    Mcmanis, P.G.3
  • 22
    • 0023920586 scopus 로고
    • Controlled-release levodopa/carbidopa. III. Sinemet CR5 treatment response fluctuations in Parkinson's disease
    • Cedarbaum JM, Hoey M, Kutt H, et al. Controlled-release levodopa/carbidopa. III. Sinemet CR5 treatment response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:168-173
    • (1988) Clin Neuropharmacol , vol.11 , pp. 168-173
    • Cedarbaum, J.M.1    Hoey, M.2    Kutt, H.3
  • 23
    • 0023616607 scopus 로고
    • Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease
    • Cedarbaum JM, Breck L, Kutt H, et al. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 1987;37:1607-1612
    • (1987) Neurology , vol.37 , pp. 1607-1612
    • Cedarbaum, J.M.1    Breck, L.2    Kutt, H.3
  • 26
    • 0033595549 scopus 로고    scopus 로고
    • Immediate-release and controlled-release carbidopa/levodopa in PD: A 5- Year randomized multicenter study
    • Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-1019 (Pubitemid 29442117)
    • (1999) Neurology , vol.53 , Issue.5 , pp. 1012-1019
    • Koller, W.C.1    Hutton, J.T.2    Tolosa, E.3    Capilldeo, R.4
  • 27
    • 0029732865 scopus 로고    scopus 로고
    • Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation
    • Pappert EJ, Goetz CG, Niederman F, et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47:493-495 (Pubitemid 26422542)
    • (1996) Neurology , vol.47 , Issue.6 , pp. 1493-1495
    • Pappert, E.J.1    Goetz, C.G.2    Niederman, F.3    Ling, Z.D.4    Stebbins, G.T.5    Carvey, P.M.6
  • 28
    • 0030071016 scopus 로고    scopus 로고
    • Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical use
    • DOI 10.1002/mds.870110106
    • Pappert EJ, Buhrfiend C, Lipton JW, et al. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord 1996;11:24-26 (Pubitemid 26008559)
    • (1996) Movement Disorders , vol.11 , Issue.1 , pp. 24-26
    • Pappert, E.J.1    Buhrfiend, C.2    Lipton, J.W.3    Carvey, P.M.4    Stebbins, G.T.5    Goetz, C.G.6
  • 29
    • 0028071369 scopus 로고
    • Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa
    • DOI 10.1002/mds.870090416
    • Metman LV, Hoff J, Mouradian MM, et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-465 (Pubitemid 24238378)
    • (1994) Movement Disorders , vol.9 , Issue.4 , pp. 463-465
    • Metman, L.V.1    Hoff, J.2    Mouradian, M.M.3    Chase, T.N.4
  • 34
    • 1842575746 scopus 로고    scopus 로고
    • Management of motor complications in Parkinson's disease
    • Dewey JRB. Management of motor complications in Parkinson's disease. Neurology 2004;62:S3-7
    • (2004) Neurology , vol.62
    • Dewey, J.R.B.1
  • 35
    • 20444489689 scopus 로고    scopus 로고
    • Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
    • DOI 10.1002/mds.20458
    • Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20:S11-6 (Pubitemid 40846906)
    • (2005) Movement Disorders , vol.20 , Issue.SUPPL. 11
    • Jankovic, J.1
  • 36
    • 34547191858 scopus 로고    scopus 로고
    • Medical management of levodopa-associated motor complications in patients with Parkinson's disease
    • DOI 10.2165/00023210-200721080-00005
    • Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's Disease. CNS Drugs 2007;21:677-692 (Pubitemid 47121793)
    • (2007) CNS Drugs , vol.21 , Issue.8 , pp. 677-692
    • Jankovic, J.1    Stacy, M.2
  • 37
    • 0036869650 scopus 로고    scopus 로고
    • Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
    • DOI 10.1002/mds.10244
    • McColl CD, Reardon KA, Shiff M, et al. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002;17:1227-1234 (Pubitemid 36041336)
    • (2002) Movement Disorders , vol.17 , Issue.6 , pp. 1227-1234
    • McColl, C.D.1    Reardon, K.A.2    Shiff, M.3    Kempster, P.A.4
  • 38
    • 4243094853 scopus 로고    scopus 로고
    • Long term motor complications of levodopa: Clinical features, mechanisms, and management strategies
    • DOI 10.1136/pgmj.2003.013912
    • Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 2004;80:452-458 (Pubitemid 39108037)
    • (2004) Postgraduate Medical Journal , vol.80 , Issue.946 , pp. 452-458
    • Thanvi, B.R.1    Lo, T.C.N.2
  • 39
    • 33344469306 scopus 로고    scopus 로고
    • Pharmacokinetic optimisation in the treatment of Parkinson's disease: An update
    • DOI 10.2165/00003088-200645020-00001
    • Nyholm D. Pharmacokinetic optimization in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45:109-136 • An authoritative overview of the strategies for optimization of the treatment of PD, with a focus on pharmacokinetics of LD and DA agonists. (Pubitemid 43290827)
    • (2006) Clinical Pharmacokinetics , vol.45 , Issue.2 , pp. 109-136
    • Nyholm, D.1
  • 40
    • 0030970473 scopus 로고    scopus 로고
    • Using liquid levodopa in the treatment of Parkinson's disease. a practical guide
    • Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease: a practical guide. Drugs Aging 1997;10:332-340 (Pubitemid 27202084)
    • (1997) Drugs and Aging , vol.10 , Issue.5 , pp. 332-340
    • Kurth, M.C.1
  • 41
    • 20844454214 scopus 로고    scopus 로고
    • Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study
    • DOI 10.1001/archneur.62.6.905
    • Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910 (Pubitemid 40973452)
    • (2005) Archives of Neurology , vol.62 , Issue.6 , pp. 905-910
    • Stocchi, F.1    Vacca, L.2    Ruggieri, S.3    Olanow, C.W.4
  • 44
    • 34548819330 scopus 로고    scopus 로고
    • The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
    • DOI 10.1016/j.parkreldis.2007.06.005, PII S1353802007001071
    • Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13:13-17 (Pubitemid 47444538)
    • (2007) Parkinsonism and Related Disorders , vol.13 , Issue.SUPPL. SEPT
    • Nyholm, D.1
  • 45
    • 20844454214 scopus 로고    scopus 로고
    • Infusion of levodopa methyl ester in patients with advanced PD: A clinical and pharmacokinetic study
    • Stocchi F, Vacca L, Ruggieri S, et al. Infusion of levodopa methyl ester in patients with advanced PD: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910
    • (2005) Arch Neurol , vol.62 , pp. 905-910
    • Stocchi, F.1    Vacca, L.2    Ruggieri, S.3
  • 46
    • 0022474704 scopus 로고
    • Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: Preliminary observations
    • Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-265 (Pubitemid 16044214)
    • (1986) Annals of Neurology , vol.20 , Issue.2 , pp. 262-265
    • Kurlan, R.1    Rubin, A.J.2    Miller, C.3
  • 47
  • 48
    • 0024319943 scopus 로고
    • Jejunal delivery of levodopa methylester
    • Ruggieri S, Stocchi F, Carta A, et al. Jejunal delivery of levodopa methylester. Lancet 1989;8653:45-46
    • (1989) Lancet , vol.8653 , pp. 45-46
    • Ruggieri, S.1    Stocchi, F.2    Carta, A.3
  • 49
    • 0031906233 scopus 로고    scopus 로고
    • Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
    • DOI 10.1002/mds.870130222
    • Syed N, Murphy J, Zimmerman T, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338 (Pubitemid 28127812)
    • (1998) Movement Disorders , vol.13 , Issue.2 , pp. 336-338
    • Syed, N.1    Murphy, J.2    Zimmerman Jr., T.3    Mark, M.H.4    Sage, J.I.5
  • 50
    • 0027518164 scopus 로고
    • Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations
    • Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-1703
    • (1993) Neurology , vol.43 , pp. 1698-1703
    • Kurth, M.C.1    Tetrud, J.W.2    Tanner, C.M.3
  • 51
    • 67649128110 scopus 로고    scopus 로고
    • Duodopa® website. Available from: Last accessed 6 October 2008
    • Duodopa® website. Available from: www.duodopa.com [Last accessed 6 October 2008]
  • 52
    • 12544252127 scopus 로고    scopus 로고
    • Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
    • Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223
    • (2005) Neurology , vol.64 , pp. 216-223
    • Nyholm, D.1    Nilsson Remahl, A.I.2    Dizdar, N.3
  • 54
    • 34047239617 scopus 로고    scopus 로고
    • Duodenal levodopa infusion for the treatment of Parkinson's disease
    • DOI 10.1517/14656566.8.5.657
    • Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-664 (Pubitemid 46547018)
    • (2007) Expert Opinion on Pharmacotherapy , vol.8 , Issue.5 , pp. 657-664
    • Samanta, J.1    Hauser, R.A.2
  • 55
    • 0024384156 scopus 로고
    • Continuous levodopa infusions to treat complex dystonia in Parkinson's disease
    • Sage JL, Mchale DM, Sonsalla P, et al. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989;39:888-891 (Pubitemid 19170409)
    • (1989) Neurology , vol.39 , Issue.7 , pp. 888-891
    • Sage, J.I.1    McHale, D.M.2    Sonsalla, P.3    Vitagliano, D.4    Heikkila, R.E.5
  • 57
    • 41749084435 scopus 로고    scopus 로고
    • Enteral levodopa/carbidopa infusion in advanced Parkinson disease: Long-term exposure
    • Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73
    • (2008) Clin Neuropharmacol , vol.31 , pp. 63-73
    • Nyholm, D.1    Lewander, T.2    Johansson, A.3
  • 59
    • 0036742384 scopus 로고    scopus 로고
    • Improved stability and release control of levodopa and metaraminol using ion exchange fibers and transdermal iontophoresis
    • Kankkunen T, Huupponen I, Lahtinen K, et al. Improved stability and release control of levodopa and metaraminol using ion exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 2002;16:273-280
    • (2002) Eur J Pharm Sci , vol.16 , pp. 273-280
    • Kankkunen, T.1    Huupponen, I.2    Lahtinen, K.3
  • 60
    • 0025200701 scopus 로고
    • Levodopa delivery from controlled-release polymer matrix: Delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats
    • Sabel BA, Dominiak P, Haeuser W, et al. Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J Pharmacol Exp Ther 1990;255:914-922
    • (1990) J Pharmacol Exp Ther , vol.255 , pp. 914-922
    • Sabel, B.A.1    Dominiak, P.2    Haeuser, W.3
  • 61
    • 0015855006 scopus 로고
    • L-dopa level in plasma, primary condition for the kinetic effect
    • Birkmayer W, Danielcyk W, Neumayer E, et al. L-dopa level in plasma, primary condition for the kinetic effect. J Neural Transm 1973;34:133-143
    • (1973) J Neural Transm , vol.34 , pp. 133-143
    • Birkmayer, W.1    Danielcyk, W.2    Neumayer, E.3
  • 62
    • 0023727878 scopus 로고
    • The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats
    • DOI 10.1023/A:1015946114321
    • Leppert PS, Cortese M, Fix JA. The effects of carbidopa dose and time and route of administration on systemic L-Dopa levels in rats. Pharm Res 1988;5:587-591 (Pubitemid 18259216)
    • (1988) Pharmaceutical Research , vol.5 , Issue.9 , pp. 587-591
    • Leppert, P.S.1    Cortese, M.2    Fix, J.A.3
  • 63
    • 0019863875 scopus 로고
    • Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs
    • DOI 10.1002/jps.2600700705
    • Sasahara K, Nitanai T, Habara T, et al. Dosage form design for improvement of bioavailability of levodopa IV: possible causes of low bioavailability of oral levodopa in dogs. J Pharm Sci 1981;70:730-733 (Pubitemid 11059041)
    • (1981) Journal of Pharmaceutical Sciences , vol.70 , Issue.7 , pp. 730-733
    • Sasahara, K.1    Nitanai, T.2    Habara, T.3
  • 65
    • 0017703270 scopus 로고
    • Improved delivery through biological membranes. 4. Prodrugs of L Dopa
    • DOI 10.1021/jm00221a014
    • Bordor N, Sloan KB, Higuchi T, et al. Improved delivery through biological membranes 4: prodrugs of L-dopa. J Med Chem 1977;20:1435-1445 (Pubitemid 8209552)
    • (1977) Journal of Medicinal Chemistry , vol.20 , Issue.11 , pp. 1435-1445
    • Bodor, N.1    Sloan, K.B.2    Higuchi, T.3    Sasahara, K.4
  • 66
    • 33947201622 scopus 로고    scopus 로고
    • Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms
    • DOI 10.1016/j.ijpharm.2006.10.018, PII S0378517306008842
    • Goole J, Vanderbist F, Amighi K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. Int J Pharm 2007;334:35-41 (Pubitemid 46420403)
    • (2007) International Journal of Pharmaceutics , vol.334 , Issue.1-2 , pp. 35-41
    • Goole, J.1    Vanderbist, F.2    Amighi, K.3
  • 67
    • 0028805325 scopus 로고
    • Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug
    • Wang H, Lee J, Tsai M, et al. Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug. Bioorg Med Chem Lett 1995;5:2195-2198
    • (1995) Bioorg Med Chem Lett , vol.5 , pp. 2195-2198
    • Wang, H.1    Lee, J.2    Tsai, M.3
  • 69
    • 0021340573 scopus 로고
    • L-Dopa methyl ester - A candidate for chronic systemic delivery of L-dopa in Parkinson's disease
    • Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-Dopa methyl ester - a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol 1984;7:89-98 (Pubitemid 14138570)
    • (1984) Clinical Neuropharmacology , vol.7 , Issue.1 , pp. 89-98
    • Cooper, D.R.1    Marrel, C.2    Testa, B.3
  • 70
    • 85012490929 scopus 로고
    • A lymphotropic prodrug of L-dopa: Synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3, 4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol
    • Garzon-Aburbeh A, Poupaert JH, Claesen M, et al. A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3, 4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. J Med Chem 1986;29:687-691
    • (1986) J Med Chem , vol.29 , pp. 687-691
    • Garzon-Aburbeh, A.1    Poupaert, J.H.2    Claesen, M.3
  • 72
    • 0023225184 scopus 로고
    • L-Dopa esters as potential prodrugs: Behavioural activity in experimental models of Parkinson's disease
    • Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J Pharm Pharmacol 1987;39:627-635 (Pubitemid 17116308)
    • (1987) Journal of Pharmacy and Pharmacology , vol.39 , Issue.8 , pp. 627-635
    • Cooper, D.R.1    Marrel, C.2    Van De Waterbeemd, H.3
  • 75
    • 0026766041 scopus 로고
    • Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease
    • Stocchi F, Ruggieri S, Carta A, et al. Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease. Mov Disord 1992;7:249-256
    • (1992) Mov Disord , vol.7 , pp. 249-256
    • Stocchi, F.1    Ruggieri, S.2    Carta, A.3
  • 76
    • 0030006032 scopus 로고    scopus 로고
    • Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease
    • DOI 10.1002/ana.410390321
    • Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;39:400-404 (Pubitemid 26100768)
    • (1996) Annals of Neurology , vol.39 , Issue.3 , pp. 400-404
    • Djaldetti, R.1    Melamed, E.2
  • 78
    • 49449113969 scopus 로고    scopus 로고
    • Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs
    • More SS, Vince R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs. J Med Chem 2008;51:4581-4588
    • (2008) J Med Chem , vol.51 , pp. 4581-4588
    • More, S.S.1    Vince, R.2
  • 80
    • 52449092612 scopus 로고    scopus 로고
    • New L-Dopa codrugs as potential antiparkinson agents
    • Sozio P, Iannitelli A, Cerasa LS, et al. New L-Dopa codrugs as potential antiparkinson agents. Arch Pharm 2008;341:412-417
    • (2008) Arch Pharm , vol.341 , pp. 412-417
    • Sozio, P.1    Iannitelli, A.2    Cerasa, L.S.3
  • 83
    • 0036460167 scopus 로고    scopus 로고
    • Dopamine agonists and neuroprotection in Parkinson's disease
    • DOI 10.1046/j.1468-1331.9.s3.9.x
    • Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 2002;9:7-14 (Pubitemid 35471978)
    • (2002) European Journal of Neurology , vol.9 , Issue.SUPPL. 3 , pp. 7-14
    • Schapira, A.H.V.1
  • 84
    • 0037176885 scopus 로고    scopus 로고
    • Neuroprotection and dopamine agonists
    • Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002;58:S9-S18
    • (2002) Neurology , vol.58
    • Schapira, A.H.1
  • 85
    • 0141856229 scopus 로고    scopus 로고
    • Neuroprotection in PD a role for dopamine agonists?
    • Schapira AH. Neuroprotection in PD a role for dopamine agonists? Neurology 2003;61:34-42
    • (2003) Neurology , vol.61 , pp. 34-42
    • Schapira, A.H.1
  • 87
    • 34248221738 scopus 로고    scopus 로고
    • Controversies of dopamine agonists: Somnolence, cardiac valvulopathy and repetitive behaviors
    • Jain S, Water CH. Controversies of dopamine agonists: somnolence, cardiac valvulopathy and repetitive behaviors. Curr Drug Ther 2007;2:17-20 (Pubitemid 46723134)
    • (2007) Current Drug Therapy , vol.2 , Issue.1 , pp. 17-20
    • Jain, S.1    Waters, C.H.2
  • 88
    • 0037208619 scopus 로고    scopus 로고
    • Are there clinically significant differences between dopamine agonists
    • Stocchi F, Vacca L, Onofrj M. Are there clinically significant differences between dopamine agonists. Adv Neurol 2003;91:259-266
    • (2003) Adv Neurol , vol.91 , pp. 259-266
    • Stocchi, F.1    Vacca, L.2    Onofrj, M.3
  • 89
    • 34548282615 scopus 로고    scopus 로고
    • Apomorphine in the treatment of Parkinson's disease
    • DOI 10.1517/14656566.8.12.1941
    • Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-1950 (Pubitemid 47321525)
    • (2007) Expert Opinion on Pharmacotherapy , vol.8 , Issue.12 , pp. 1941-1950
    • Menon, R.1    Stacy, M.2
  • 90
    • 36049001110 scopus 로고    scopus 로고
    • Apomorphine therapy in parkinson's disease: A review
    • DOI 10.1517/14656566.8.16.2799
    • Ul HI, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson's disease: a review. Expert Opin Pharmacother 2007;8:2799-2809 (Pubitemid 350193718)
    • (2007) Expert Opinion on Pharmacotherapy , vol.8 , Issue.16 , pp. 2799-2809
    • Ul Haq, I.1    Lewitt, P.A.2    Fernandez, H.H.3
  • 91
    • 0032851760 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease
    • DOI 10.2165/00003088-199937030-00004
    • Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37:257-271 (Pubitemid 29452757)
    • (1999) Clinical Pharmacokinetics , vol.37 , Issue.3 , pp. 257-271
    • Neef, C.1    Van Laar, T.2
  • 92
    • 33744465789 scopus 로고    scopus 로고
    • Update on apomorphine for the rapid treatment of hypomobility ('Off') episodes in Parkinson's disease
    • DOI 10.1592/phco.26.6.840
    • Obering CD, Chen JJ, Swope DM. Update on apomorphine for the rapid treatment of hypomobility ('Off') episodes in Parkinson's Disease. Pharmacotherapy 2006;26:840-852 (Pubitemid 43807635)
    • (2006) Pharmacotherapy , vol.26 , Issue.6 I , pp. 840-852
    • Obering, C.D.1    Chen, J.J.2    Swope, D.M.3
  • 93
    • 33748981339 scopus 로고    scopus 로고
    • Apomorphine: A rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease
    • DOI 10.1097/01.WNF.0000220824.57769.E5, PII 0000282620060900000008
    • Kolls BJ, Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson Disease. Clin Neuropharmacol 2006;29:292-301 (Pubitemid 44440003)
    • (2006) Clinical Neuropharmacology , vol.29 , Issue.5 , pp. 292-301
    • Kolls, B.J.1    Stacy, M.2
  • 94
    • 34249883912 scopus 로고    scopus 로고
    • Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
    • DOI 10.1016/j.jns.2007.03.013, PII S0022510X07002158
    • Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258:137-143 (Pubitemid 46874490)
    • (2007) Journal of the Neurological Sciences , vol.258 , Issue.1-2 , pp. 137-143
    • Pahwa, R.1    Koller, W.C.2    Trosch, R.M.3    Sherry, J.H.4
  • 95
    • 43749088474 scopus 로고    scopus 로고
    • Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: A 6-month open-label study
    • • An investigation on the long-term efficacy and safety of apomorphine administered via subcutaneous route in advanced PD patients
    • Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study. CNS Drugs 2008;22(6):519-527 • An investigation on the long-term efficacy and safety of apomorphine administered via subcutaneous route in advanced PD patients.
    • (2008) CNS Drugs , vol.22 , Issue.6 , pp. 519-527
    • Trosch, R.M.1    Silver, D.2    Bottini, P.B.3
  • 96
    • 67649113810 scopus 로고    scopus 로고
    • website. Available from
    • Apokyn website. Available from: www.apokyn.com/
  • 97
    • 67649093740 scopus 로고    scopus 로고
    • website. Available from
    • Apo-go website. Available from: www.apo-go.co.uk/index.htm.
  • 98
    • 44249093494 scopus 로고    scopus 로고
    • Apomorphine for the acute treatment of 'off' episodes in Parkinson's disease
    • Stacya M, Silver D. Apomorphine for the acute treatment of 'off' episodes in Parkinson's disease. Parkinsonism Relat Disord 2008;14:85-92
    • (2008) Parkinsonism Relat Disord , vol.14 , pp. 85-92
    • Stacya, M.1    Silver, D.2
  • 99
    • 0036869028 scopus 로고    scopus 로고
    • Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
    • DOI 10.1002/mds.10281
    • Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's Disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241 (Pubitemid 36041337)
    • (2002) Movement Disorders , vol.17 , Issue.6 , pp. 1235-1241
    • Manson, A.J.1    Turner, K.2    Lees, A.J.3
  • 101
    • 52649108045 scopus 로고    scopus 로고
    • Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's Disease with motor fluctuations: A multicenter study
    • García Ruiz PJ, Sesar Ignacio Á, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's Disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136
    • (2008) Mov Disord , vol.23 , pp. 1130-1136
    • García Ruiz, P.J.1    Sesar Ignacio, Á.2    Ares Pensado, B.3
  • 104
    • 1842575713 scopus 로고    scopus 로고
    • Practical considerations in the use of apomorphine injectable
    • Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62:S32-6 (Pubitemid 38419833)
    • (2004) Neurology , vol.62 , Issue.6 SUPPL. 4
    • Bowron, A.1
  • 106
    • 67649117493 scopus 로고    scopus 로고
    • Available from
    • Britannia products in developments. Available from: www.britannia-pharm. co.uk/partnerships.shtml#Apo-nasal%20PD.
    • Britannia Products in Developments
  • 107
    • 33748317921 scopus 로고    scopus 로고
    • Clinical studies with ropinirole in Parkinson's disease and RLS
    • DOI 10.1007/s00415-006-4004-4
    • Jost WH, Angersbach D, Rascol O. Clinical studies with ropinirole in Parkinson's disease and RLS. J Neurol 2006;253:16-21 (Pubitemid 44327086)
    • (2006) Journal of Neurology , vol.253 , Issue.SUPPL. 4
    • Jost, W.H.1    Angersbach, D.2    Rascol, O.3
  • 108
    • 30744474230 scopus 로고    scopus 로고
    • Ropinirole, a non-ergoline dopamine agonist
    • Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005;11:253-272
    • (2005) CNS Drug Rev , vol.11 , pp. 253-272
    • Jost, W.H.1    Angersbach, D.2
  • 109
    • 0033663588 scopus 로고    scopus 로고
    • Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease
    • Hubble J, Koller WC, Atchison P, et al. Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol 2000;40:641-646
    • (2000) J Clin Pharmacol , vol.40 , pp. 641-646
    • Hubble, J.1    Koller, W.C.2    Atchison, P.3
  • 110
    • 67649132254 scopus 로고    scopus 로고
    • website. Available from
    • RequipXL website. Available from: www.requipxl.com/
  • 111
    • 34147154059 scopus 로고    scopus 로고
    • Ropinirole 24-hour prolonged release. Randomized, controlled study in advanced Parkinson disease
    • • Evaluation of ropinirole 24-hour prolonged release as an adjunct to LD in patients with PD and motor fluctuations
    • Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release. Randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115 • Evaluation of ropinirole 24-hour prolonged release as an adjunct to LD in patients with PD and motor fluctuations.
    • (2007) Neurology , vol.68 , pp. 1108-1115
    • Pahwa, R.1    Stacy, M.A.2    Factor, S.A.3
  • 112
    • 44949178691 scopus 로고    scopus 로고
    • Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease
    • DOI 10.2165/00023210-200822070-00003
    • Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008;22:563-586 (Pubitemid 351822118)
    • (2008) CNS Drugs , vol.22 , Issue.7 , pp. 563-586
    • Gallagher, D.A.1    Schrag, A.2
  • 113
    • 24144502098 scopus 로고    scopus 로고
    • Alternatives to levodopa in the initial treatment of early Parkinson's disease
    • DOI 10.2165/00002512-200522090-00002
    • Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005;22:731-740 (Pubitemid 41242117)
    • (2005) Drugs and Aging , vol.22 , Issue.9 , pp. 731-740
    • Lees, A.1
  • 114
    • 18344398824 scopus 로고    scopus 로고
    • Anticholinergics for symptomatic management of Parkinson's disease
    • CD003735
    • Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;3:CD003735
    • (2003) Cochrane Database Syst Rev , vol.3
    • Katzenschlager, R.1    Sampaio, C.2    Costa, J.3
  • 116
    • 0036920178 scopus 로고    scopus 로고
    • Management of Parkinson's disease: An evidence-based review
    • Movement Disorders Society Evidence-Based Review
    • Movement Disorders Society Evidence-Based Review. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;7:1-166
    • (2002) Mov Disord , vol.7 , pp. 1-166
  • 117
    • 0030669245 scopus 로고    scopus 로고
    • Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: A double-blind, placebo-controlled, multicenter trial
    • Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the wearing off phenomenon: a double blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071 (Pubitemid 27456089)
    • (1997) Neurology , vol.49 , Issue.4 , pp. 1066-1071
    • Rajput, A.H.1    Martin, W.2    Saint-Hilaire, M.-H.3    Dorflinger, E.4    Pedder, S.5
  • 119
    • 19344378940 scopus 로고    scopus 로고
    • Entacapone in the treatment of Parkinson's disease
    • DOI 10.1016/S1474-4422(05)70098-3, PII S1474442205700983
    • Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005;4:366-370 (Pubitemid 40720033)
    • (2005) Lancet Neurology , vol.4 , Issue.6 , pp. 366-370
    • Schrag, A.1
  • 120
    • 0016414699 scopus 로고
    • Potentiation of the anti-akinetic effect after L-Dopa treatment by an inhibitor of MAO-B, deprenil
    • Birkmayer W, Riederer P, Youdim MBH, et al. Potentiation of the anti-akinetic effect after L-Dopa treatment by an inhibitor of MAO-B, deprenil. J Neural Transm 1975;36:303-323
    • (1975) J Neural Transm , vol.36 , pp. 303-323
    • Birkmayer, W.1    Riederer, P.2    Youdim, M.B.H.3
  • 121
    • 0017345412 scopus 로고
    • Implications of combined treatment with 'Madopar' and L deprenil in Parkinson's disease. a long term study
    • Birkmayer W, Riederer P, Ambrozi L, et al. Implications of combined treatment with Madopar and deprenil in Parkinson's disease; a long-term study. Lancet 1977;1:434-443 (Pubitemid 8045120)
    • (1977) Lancet , vol.1 , Issue.8009 , pp. 439-442
    • Birkmayer, W.1    Riederer, P.2    Ambroziyoudim, L.M.B.H.3
  • 122
    • 0017729733 scopus 로고
    • Deprenyl in Parkinson's disease
    • Lees AJ, Shaw KM, Kohout LIJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795 (Pubitemid 8193248)
    • (1977) Lancet , vol.2 , Issue.8042 , pp. 791-795
    • Lees, A.J.1    Shaw, K.M.2    Kohout, L.J.3
  • 123
    • 0018840087 scopus 로고
    • Deprenyl is selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease
    • Reiderer P, Reynolds GP. Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease. Br J Clin Pharmacol 1980;9:98-99 (Pubitemid 10164684)
    • (1980) British Journal of Clinical Pharmacology , vol.9 , Issue.1 , pp. 98-99
    • Reiderer, P.1    Reynolds, G.P.2
  • 124
    • 0018068203 scopus 로고
    • Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration
    • Reynolds GP, Riederer P, Sandler M, et al. Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration. J Neural Transm 1978;43:271-277 (Pubitemid 9050088)
    • (1978) Journal of Neural Transmission - General Section , vol.43 , Issue.3-4 , pp. 271-277
    • Reynolds, G.P.1    Riederer, P.2    Sandler, M.3
  • 125
    • 34247324279 scopus 로고    scopus 로고
    • Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
    • Lew MF, Pahwa R, Leehey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23:741-750
    • (2007) Curr Med Res Opin , vol.23 , pp. 741-750
    • Lew, M.F.1    Pahwa, R.2    Leehey, M.3
  • 126
    • 34848857679 scopus 로고    scopus 로고
    • Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms
    • DOI 10.1097/WNF.0b013e3180616570, PII 0000282620070900000007
    • Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. Clin Neuropharmacol 2007;30:295-300 (Pubitemid 47511510)
    • (2007) Clinical Neuropharmacology , vol.30 , Issue.5 , pp. 295-300
    • Ondo, W.G.1    Sethi, K.D.2    Kricorian, G.3
  • 127
    • 2342426425 scopus 로고    scopus 로고
    • Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study
    • DOI 10.1002/mds.20036
    • Waters CH, Sethi KD, Hause RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-432 (Pubitemid 38559645)
    • (2004) Movement Disorders , vol.19 , Issue.4 , pp. 426-432
    • Waters, C.H.1    Sethi, K.D.2    Hauser, R.A.3    Molho, E.4    Bertoni, J.M.5
  • 132
    • 15844386001 scopus 로고    scopus 로고
    • Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
    • DOI 10.1016/S0140-6736(05)71083-7, PII S0140673605710837
    • Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954 (Pubitemid 41071428)
    • (2005) Lancet , vol.365 , Issue.9463 , pp. 947-954
    • Rascol, O.1    Brooks, D.J.2    Melamed, E.3    Oertel, W.4    Poewe, W.5    Stocchi, F.6    Tolosa, E.7
  • 133
    • 13444302612 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study
    • DOI 10.1001/archneur.62.2.241
    • Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch Neurol 2005;62:241-248 (Pubitemid 40204745)
    • (2005) Archives of Neurology , vol.62 , Issue.2 , pp. 241-248
    • Schwid, S.R.1
  • 134
    • 0037734329 scopus 로고    scopus 로고
    • Neuroprotection by deprenyl and other propargylamines: Glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B
    • DOI 10.1007/s00702-002-0827-z
    • Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110:509-515 (Pubitemid 36543282)
    • (2003) Journal of Neural Transmission , vol.110 , Issue.5 , pp. 509-515
    • Tatton, W.1    Chalmers-Redman, R.2    Tatton, N.3
  • 136
    • 61449173973 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's Disease (The ADAGIO Study): Rationale, design, and baseline characteristics
    • Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's Disease (The ADAGIO Study): rationale, design, and baseline characteristics. Mov Disord 2008;23:2194-2201
    • (2008) Mov Disord , vol.23 , pp. 2194-2201
    • Olanow, C.W.1    Hauser, R.A.2    Jankovic, J.3
  • 138
    • 0026751312 scopus 로고
    • Amantadine as a N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic application?
    • Stoof JC, Booij J, Drukarch B. Amantadine as a N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic application? Clin Neurol Neurosurg 1992;92:S4-6
    • (1992) Clin Neurol Neurosurg , vol.92
    • Stoof, J.C.1    Booij, J.2    Drukarch, B.3
  • 139
    • 22544444943 scopus 로고    scopus 로고
    • A novel dopamine agonist for the transdermal treatment of Parkinson's disease
    • Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65:3-5 (Pubitemid 41022399)
    • (2005) Neurology , vol.65 , Issue.2 SUPPL. 1
    • Jenner, P.1
  • 140
    • 0028324501 scopus 로고
    • 2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease
    • Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9:147-154 (Pubitemid 24092329)
    • (1994) Movement Disorders , vol.9 , Issue.2 , pp. 147-154
    • Belluzzi, J.D.1    Domino, E.F.2    May, J.M.3    Bankiewicz, K.S.4    McAfee, D.A.5
  • 141
    • 34247208187 scopus 로고    scopus 로고
    • Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
    • DOI 10.1212/01.wnl.0000259516.61938.bb, PII 0000611420070417000008
    • LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system PREFER Study. Neurology 2007;68:1262-1267 (Pubitemid 46625971)
    • (2007) Neurology , vol.68 , Issue.16 , pp. 1262-1267
    • Lewitt, P.A.1    Lyons, K.E.2    Pahwa, R.3
  • 142
    • 33846438955 scopus 로고    scopus 로고
    • Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
    • DOI 10.1212/01.wnl.0000252355.79284.22, PII 0000611420070123000009
    • Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276 (Pubitemid 46148338)
    • (2007) Neurology , vol.68 , Issue.4 , pp. 272-276
    • Watts, R.L.1    Jankovic, J.2    Waters, C.3    Rajput, A.4    Boroojerdi, B.5    Rao, J.6
  • 143
    • 34248372064 scopus 로고    scopus 로고
    • Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial
    • DOI 10.1016/S1474-4422(07)70108-4, PII S1474442207701084
    • Poewe WH, Rascol O, Quinn N, et al. The SP 515 Investigators, efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol 2007;6:513-520 (Pubitemid 46734759)
    • (2007) Lancet Neurology , vol.6 , Issue.6 , pp. 513-520
    • Poewe, W.H.1    Rascol, O.2    Quinn, N.3    Tolosa, E.4    Oertel, W.H.5    Martignoni, E.6    Rupp, M.7    Boroojerdi, B.8
  • 144
    • 33748753171 scopus 로고    scopus 로고
    • Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: Subanalysis of a parallel group, open-label, dose-escalation study
    • DOI 10.1097/01.WNF.0000228179.83335.65, PII 0000282620060700000009
    • Babic T, Boothmann B, Polivka J, et al. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol 2006;29:238-242 (Pubitemid 44510461)
    • (2006) Clinical Neuropharmacology , vol.29 , Issue.4 , pp. 238-242
    • Babic, T.1    Boothmann, B.2    Polivka, J.3    Rektor, I.4    Boroojerdi, B.5    Hack, H.-J.6    Randerath, O.7
  • 146
    • 0035353743 scopus 로고    scopus 로고
    • Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study
    • Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001;16:459-463
    • (2001) Mov Disord , vol.16 , pp. 459-463
    • Hutton, J.T.1    Metman, L.V.2    Chase, T.N.3
  • 147
    • 34249033784 scopus 로고    scopus 로고
    • Transdermal rotigotine: Double-blind, placebo-controlled trial in Parkinson disease
    • DOI 10.1001/archneur.64.5.676
    • Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-682 (Pubitemid 46789833)
    • (2007) Archives of Neurology , vol.64 , Issue.5 , pp. 676-682
    • Jankovic, J.1    Watts, R.L.2    Martin, W.3    Boroojerdi, B.4
  • 148
    • 21544434051 scopus 로고    scopus 로고
    • Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease
    • DOI 10.1097/01.wnf.0000162228.00154.ba
    • Gueldenpfennig WM, Poole KH, Sommerville KW, et al. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson Disease. Clin Neuropharmacol 2005;28:106-110 (Pubitemid 40923407)
    • (2005) Clinical Neuropharmacology , vol.28 , Issue.3 , pp. 106-110
    • Guldenpfennig, W.M.1    Poole, K.H.2    Sommerville, K.W.3    Boroojerdi, B.4
  • 149
    • 67649123875 scopus 로고    scopus 로고
    • website. Available from: Last accessed 21 March 2008
    • Neupro website. Available from: www.neupro.com/Home/Home.asp [Last accessed 21 March 2008]
  • 151
    • 38749085263 scopus 로고    scopus 로고
    • Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease
    • • Investigation on potential neuroprotective property of rotigotine in MPTP-lesioned animal
    • Scheller D, Stichel-Gunkel C, Lübbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci Lett 2008;432:30-34 • Investigation on potential neuroprotective property of rotigotine in MPTP-lesioned animal
    • (2008) Neurosci Lett , vol.432 , pp. 30-34
    • Scheller, D.1    Stichel-Gunkel, C.2    Lübbert, H.3
  • 152
    • 0033934595 scopus 로고    scopus 로고
    • Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease
    • Allain H, Destée A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. Eur Neurol 2000;44:22-30 (Pubitemid 30456788)
    • (2000) European Neurology , vol.44 , Issue.1 , pp. 22-30
    • Allain, H.1    Destee, A.2    Petit, H.3    Patay, M.4    Schuck, S.5    Bentue-Ferrer, D.6    Le Cavorzin, P.7
  • 154
    • 0026668816 scopus 로고
    • Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease
    • Heinz A, Suchy I, Klewin I, et al. Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease. J Neural Transm 1992;4:291-301
    • (1992) J Neural Transm , vol.4 , pp. 291-301
    • Heinz, A.1    Suchy, I.2    Klewin, I.3
  • 156
    • 0026457051 scopus 로고
    • Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease
    • Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781
    • (1992) Ann Neurol , vol.32 , pp. 776-781
    • Baronti, F.1    Mouradian, M.M.2    Davis, T.L.3
  • 157
    • 0025972525 scopus 로고
    • Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 34 patients
    • Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in
    • (1991) Brain , vol.114 , pp. 601-617
    • Vaamonde, J.1    Luquin, M.R.2    Obeso, J.A.3
  • 158
    • 0036723589 scopus 로고    scopus 로고
    • Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
    • Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-2066 (Pubitemid 34940716)
    • (2002) Brain , vol.125 , Issue.9 , pp. 2058-2066
    • Stocchi, F.1    Ruggieri, S.2    Vacca, L.3    Olanow, C.W.4
  • 159
    • 0027354148 scopus 로고
    • Apomorphine and lisuride infusion: A comparative chronic study
    • Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993;60:653-655
    • (1993) Adv Neurol , vol.60 , pp. 653-655
    • Stocchi, F.1    Bramante, L.2    Monge, A.3
  • 160
    • 0024257549 scopus 로고
    • Comparison between L-dopa and lisuride intravenous infusions: A clinical study
    • Ruggieri S, Stocchi F, Carta A, et al. Comparison between L-dopa and lisuride intravenous infusions: a clinical study. Mov Disord 1988;3:313-319
    • (1988) Mov Disord , vol.3 , pp. 313-319
    • Ruggieri, S.1    Stocchi, F.2    Carta, A.3
  • 161
    • 33750802483 scopus 로고    scopus 로고
    • Maleic- And fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation
    • DOI 10.1080/10611860600916636, PII U336L07V66514554
    • Di Stefano A, Sozio P, Iannitelli A, et al. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target 2006;14:652-661 (Pubitemid 44712361)
    • (2006) Journal of Drug Targeting , vol.14 , Issue.9 , pp. 652-661
    • Di Stefano, A.1    Sozio, P.2    Iannitelli, A.3    Marianecci, C.4    Santucci, E.5    Carafa, M.6
  • 164
    • 44749092720 scopus 로고    scopus 로고
    • Solid lipid nanoparticles as delivery systems for Bromocriptine
    • Esposito E, Fantin M, Marti M, et al. Solid lipid nanoparticles as delivery systems for Bromocriptine. Pharm Res 2008;25:1521-1530
    • (2008) Pharm Res , vol.25 , pp. 1521-1530
    • Esposito, E.1    Fantin, M.2    Marti, M.3
  • 165
    • 0021586266 scopus 로고
    • A new class of polymers: Starburst-dendritic macromolecules
    • Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: starburst-dendritic macromolecules. Polym J 1985;17:117-132
    • (1985) Polym J , vol.17 , pp. 117-132
    • Tomalia, D.A.1    Baker, H.2    Dewald, J.3
  • 166
    • 0025373701 scopus 로고
    • Starbust dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter
    • Tomalia DA, Naylor AM, Goddard WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 1990;29:138-175 (Pubitemid 20142204)
    • (1990) Angewandte Chemie - International Edition in English , vol.29 , Issue.2 , pp. 138-175
    • Tomalia, D.A.1    Naylor, A.M.2    Goddard III, W.A.3
  • 167
    • 33750080477 scopus 로고    scopus 로고
    • Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers
    • DOI 10.1021/ol061449l
    • Tang S, Martinez LJ, Sharma MA, et al. Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers. Org Lett 2006;8:4421-4424 (Pubitemid 44578642)
    • (2006) Organic Letters , vol.8 , Issue.20 , pp. 4421-4424
    • Tang, S.1    Martinez, L.J.2    Sharma, A.3    Chai, M.4
  • 168
    • 0034095651 scopus 로고    scopus 로고
    • Transport of drugs from the nasal cavity to the central nervous system
    • DOI 10.1016/S0928-0987(00)00087-7, PII S0928098700000877
    • Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18 (Pubitemid 30410839)
    • (2000) European Journal of Pharmaceutical Sciences , vol.11 , Issue.1 , pp. 1-18
    • Illum, L.1
  • 169
    • 3242740239 scopus 로고    scopus 로고
    • Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
    • DOI 10.1016/j.neuroscience.2004.05.029, PII S0306452204004002
    • Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insuline-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496 (Pubitemid 38950662)
    • (2004) Neuroscience , vol.127 , Issue.2 , pp. 481-496
    • Thorne, R.G.1    Pronk, G.J.2    Padmanabhan, V.3    Frey II, W.H.4
  • 170
    • 0025903316 scopus 로고
    • Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity
    • Sakane T, Akizuki M, Yoshida M, et al. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 1991;43:449-451
    • (1991) J Pharm Pharmacol , vol.43 , pp. 449-451
    • Sakane, T.1    Akizuki, M.2    Yoshida, M.3
  • 171
    • 0025944792 scopus 로고
    • The transport of drugs to the cerebrospinal fluid directly from the nasal cavity: The relation to the lipophilicity of the drug
    • Sakane T, Akizuki M, Yamashita S, et al. The transport of drugs to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:2456-2458
    • (1991) Chem Pharm Bull , vol.39 , pp. 2456-2458
    • Sakane, T.1    Akizuki, M.2    Yamashita, S.3
  • 173
    • 0033795553 scopus 로고    scopus 로고
    • Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs
    • DOI 10.1023/A:1007583422634
    • Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-Dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17:978-984 (Pubitemid 30736602)
    • (2000) Pharmaceutical Research , vol.17 , Issue.8 , pp. 978-984
    • Kao, H.D.1    Traboulsi, A.2    Itoh, S.3    Dittert, L.4    Hussain, A.5
  • 175
    • 67649113813 scopus 로고    scopus 로고
    • Schwarz Pharma press release for Parcopa® aprroval from PDA. Available from
    • Schwarz Pharma press release for Parcopa® aprroval from PDA. Available from: www.schwarzpharma.com/sp/n2345/Press-Release--August-30-2004
  • 176
    • 67649117495 scopus 로고    scopus 로고
    • website. Available from
    • Stalevo website. Available from: www.stalevo.com
  • 177
    • 67649132258 scopus 로고    scopus 로고
    • Information on V1512. Available from
    • Information on V1512. Available from: www.vernalis.com/ver/rdc2/ neurology/v1512/
  • 178
    • 33846837447 scopus 로고    scopus 로고
    • Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease
    • DOI 10.1097/01.WNF.0000236762.77913.C6, PII 0000282620070100000004
    • Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30:18-24 (Pubitemid 46204314)
    • (2007) Clinical Neuropharmacology , vol.30 , Issue.1 , pp. 18-24
    • Stocchi, F.1    Fabbri, L.2    Vecsei, L.3    Krygowska-Wajs, A.4    Monici Preti, P.A.5    Ruggieri, S.A.6
  • 181
    • 67649085495 scopus 로고    scopus 로고
    • website. Available from
    • Tasmar website. Available from: www.tasmar.com
  • 182
    • 67649098962 scopus 로고    scopus 로고
    • website. Available from
    • Comtan website. Available from: www.comtan.com
  • 183
    • 67649083305 scopus 로고    scopus 로고
    • Available from
    • Eldepryl information. Available from: www.somersetpharm.com/products/
    • Eldepryl Information
  • 184
    • 67649116054 scopus 로고    scopus 로고
    • website. Available from
    • Zelapar website. Available from: www.zelapar.com
  • 185
    • 67649134578 scopus 로고    scopus 로고
    • website. Available from
    • Azilect website. Available from: www.azilect.com
  • 186
    • 33750000049 scopus 로고    scopus 로고
    • Symptom relief in Parkinson's disease by safinamide. Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
    • Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson's disease by safinamide. Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67:24-29
    • (2006) Neurology , vol.67 , pp. 24-29
    • Stocchi, F.1    Vacca, L.2    Grassini, P.3
  • 188
    • 67649092120 scopus 로고    scopus 로고
    • website. Available from
    • Mirapex website. Available from: www.mirapex.com/
  • 189
    • 67649128105 scopus 로고    scopus 로고
    • website. Available from
    • Requip website. Available from: www.requip.com/
  • 190
    • 67649093747 scopus 로고    scopus 로고
    • website. Available from
    • Aderis Pharmaceuticals website. Available from: www.aderis.com/products/ rotigotine.htm
  • 193
    • 67649132259 scopus 로고    scopus 로고
    • Available from
    • Information on amantadine. Available from: www.endo.com/PDF/symmetrel- pack-insert.pdf
    • Information on Amantadine


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.